What is the address of Dr. CS & Dr. PVA?

The registered office of Dr. CS & Dr. PVA is located at Schriekbos 38, 2980 Zoersel.

Is Dr. CS & Dr. PVA still active?

Yes. According to the CBE (29 October 2026) Dr. CS & Dr. PVA is active, legal situation “Normale toestand”, started on 14 January 2021.

Is Dr. CS & Dr. PVA registered on Peppol?

Yes, Dr. CS & Dr. PVA is registered on the Peppol network with ID 0208:0761596686.

What is the enterprise number of Dr. CS & Dr. PVA?

The enterprise number of Dr. CS & Dr. PVA is BE0761596686.

When was Dr. CS & Dr. PVA founded?

Dr. CS & Dr. PVA was founded on 14 January 2021.

Who are the directors of Dr. CS & Dr. PVA?

According to the 2025 annual accounts, the directors of Dr. CS & Dr. PVA are: Charlotte Jan Schillebeeckx, Pieter Van Aelst.

Is Dr. CS & Dr. PVA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 14 January 2021; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Dr. CS & Dr. PVA make in 2025?

Dr. CS & Dr. PVA posted a profit after taxes of € 342,744 in financial year 2025.

What is the revenue of Dr. CS & Dr. PVA?

As a small company, Dr. CS & Dr. PVA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 466,659.

Dr. CS & Dr. PVA (Private Limited) - Zoersel

Dossier Dr. CS & Dr. PVA, printed on 29 October 2026 from databakkes.be/en/0761596686/dr-cs-dr-pva. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. CS & Dr. PVA from Zoersel, company number BE0761596686, closed financial year 2025 with a result of € 342,744 after tax. For that financial year Dr. CS & Dr. PVA recorded a gross margin of € 466,659 and equity of € 621,410. Compared with financial year 2024, the result moved from € 240,082 to € 342,744. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.

What it is worth Growing

€ 621,410

▲ 122% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 342,744

▲ 43% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 358,280

▲ 94% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 1,666 paid out

0 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 36,645

▼ 18% vs 2024

Of which on lease € 34,175.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 34,445

▼ 20% vs 2024

€ 8,749 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 24,823

▲ € 22,343 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 7,188

▲ 5% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 60,618 Gross margin 2022: € 60,618 First fiscal year in the series	€ 226,525 Gross margin 2023: € 226,525 ▲ 274% vs 2022 (€ 60,618) Favourable step	€ 320,190 Gross margin 2024: € 320,190 ▲ 41% vs 2023 (€ 226,525) Favourable step	€ 466,659 Gross margin 2025: € 466,659 ▲ 46% vs 2024 (€ 320,190) Favourable step	▲ 46%
Profit after taxes	€ 44,205 Profit after taxes 2022: € 44,205 First fiscal year in the series	€ 169,118 Profit after taxes 2023: € 169,118 ▲ 283% vs 2022 (€ 44,205) Favourable step	€ 240,082 Profit after taxes 2024: € 240,082 ▲ 42% vs 2023 (€ 169,118) Favourable step	€ 342,744 Profit after taxes 2025: € 342,744 ▲ 43% vs 2024 (€ 240,082) Favourable step	▲ 43%
Equity	€ 72,732 Equity 2022: € 72,732 First fiscal year in the series	€ 240,249 Equity 2023: € 240,249 ▲ 230% vs 2022 (€ 72,732) Favourable step	€ 280,332 Equity 2024: € 280,332 ▲ 17% vs 2023 (€ 240,249) Favourable step	€ 621,410 Equity 2025: € 621,410 ▲ 122% vs 2024 (€ 280,332) Favourable step	▲ 122%
Total debts	€ 15,975 Total debts 2022: € 15,975 First fiscal year in the series	€ 16,874 Total debts 2023: € 16,874 ▲ 6% vs 2022 (€ 15,975) Unfavourable step	€ 262,839 Total debts 2024: € 262,839 ▲ € 245,966 vs 2023 (€ 16,874) Unfavourable step	€ 80,194 Total debts 2025: € 80,194 ▼ 69% vs 2024 (€ 262,839) Favourable step	▼ 69%
Cash	€ 67,725 Cash 2022: € 67,725 First fiscal year in the series	€ 146,482 Cash 2023: € 146,482 ▲ 116% vs 2022 (€ 67,725) Favourable step	€ 185,019 Cash 2024: € 185,019 ▲ 26% vs 2023 (€ 146,482) Favourable step	€ 358,280 Cash 2025: € 358,280 ▲ 94% vs 2024 (€ 185,019) Favourable step	▲ 94%
Retained profit	€ 67,732 Retained profit 2022: € 67,732 First fiscal year in the series	€ 235,249 Retained profit 2023: € 235,249 ▲ 247% vs 2022 (€ 67,732) Favourable step	€ 275,332 Retained profit 2024: € 275,332 ▲ 17% vs 2023 (€ 235,249) Favourable step	€ 616,410 Retained profit 2025: € 616,410 ▲ 124% vs 2024 (€ 275,332) Favourable step	▲ 124%
Dividend	€ 1,600 Dividend 2022: € 1,600 First fiscal year in the series	€ 1,600 Dividend 2023: € 1,600 Unchanged (€ 1,600) Unchanged	€ 200,000 Dividend 2024: € 200,000 ▲ € 198,400 vs 2023 (€ 1,600) Unchanged	€ 1,666 Dividend 2025: € 1,666 ▼ 99% vs 2024 (€ 200,000) Unchanged	▼ 99%
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 42,894 Bank debt 2024: € 42,894 Unchanged (€ 0) Unfavourable step	€ 34,445 Bank debt 2025: € 34,445 ▼ 20% vs 2024 (€ 42,894) Favourable step	▼ 20%
Balance sheet total	€ 88,706 Balance sheet total 2022: € 88,706 First fiscal year in the series	€ 257,123 Balance sheet total 2023: € 257,123 ▲ 190% vs 2022 (€ 88,706) Unchanged	€ 543,171 Balance sheet total 2024: € 543,171 ▲ 111% vs 2023 (€ 257,123) Unchanged	€ 701,604 Balance sheet total 2025: € 701,604 ▲ 29% vs 2024 (€ 543,171) Unchanged	▲ 29%

Key figures of Dr. CS & Dr. PVA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. CS & Dr. PVA?

What happened at Dr. CS & Dr. PVA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 29, 2026 New annual accounts for financial year 2025: profit of € 342,744 (▲ 43% vs 2024). Source: NBB ↗
2022 Pieter Van Aelst became a director. NBB
2022 Charlotte Jan Schillebeeckx became a director. NBB
Jan 14, 2021 New establishment in Zoersel. KBO
Jan 14, 2021 Start of the company according to the CBE. KBO

In short

From € 44,205 profit in 2022 to € 342,744 profit in 2025.

Paid € 256,678 in corporate taxes since 2022.

Best year ever: 2025, with € 342,744 profit.

Paid out € 204,866 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Charlotte Jan Schillebeeckx Pieter Van Aelst

Dr. CS & Dr. PVA

Behind Dr. CS & Dr. PVA are Charlotte Jan Schillebeeckx and Pieter Van Aelst.

Directors

According to the 2025 annual accounts

Charlotte Jan Schillebeeckx

Director

since 2022

Pieter Van Aelst

Director

since 2022

Establishments

Establishment units

Physical locations of this company

Registered office

Schriekbos 38

2980 Zoersel

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0761.596.686
VAT number: BE 0761.596.686
Registered office: Schriekbos 38, 2980 Zoersel
Names & denominations: Dr. CS & Dr. PVA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 14 January 2021
Peppol: Active · Active since 23 Mar 2026

View on CBE Public ↗ Annual accounts (NBB) ↗